Akademik Veri Yönetim Sistemi
Turkiye Klinikleri Journal of Medical Sciences, cilt.40, sa.3, ss.366-374, 2020 (SCI-Expanded)
© 2020 by Türkiye Klinikleri.Along with the scientific and technological developments that have emerged in recent years, metabolomic studies have found themselves a place in a wide range of research fields especially includ-ing early diagnosis and treatment of diseases. Metabolites are the general names given to low molecular weight chemical components that participate in biochemical reactions or occurring as a result of biochemical reactions in the human body. The term metabolome is used to refer to all the metabolites found in the system of a body. Metabolomics is the measurement of as many metabolites as possible using advanced analytical techniques. The relevant results are evaluated statistically and compared with the control group over a determined variable such as disease status or treatment method. Thus, the change in the metabolome level is clarified, the amount of metabolites that are varying are determined and the metabolic pathways affected by the disease condition can be identified. Metabolomic research provides insight into the metabolome level, allowing the phenotype to be examined at metabolome level in addition to the genotype illuminated at genome level. This study is about the historical development of metabolomic studies, the current situation on metabolomic studies and the roles it could play in future. Current prob-lems experienced in liquid chromatography-mass spectrometry (LC-MS) based untargeted metabolomic studies, which are widely performed for biomarker discovery at metabolome level, are also evaluated within the scope of this review. In order to put into practice, the definition of liquid biopsy, which is frequently mentioned in cancer researches, studies conducted at the level of metabolome in clinical applications are of great im-portance. In the near future, the information obtained as a result of untargeted metabolomic studies will be validated with targeted studies, and many new biomarkers that can be used for early diagnosis and process examination for different diseases at the metabolome level will find their place in clinical applications.